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Abstract: One of the most important challenges in contemporary oncology is to find objective biomarkers of tumor
aggressiveness, which help to identify more invasive phenotypes of the carcinoma. The purpose of this study was to
investigate the relationships between the early and the late activation markers expression on T CD4+ and CD8+
cells subpopulations and certain clinicopathological characteristics of the neoplastic infiltration in order to deter-
mine their role as biomarkers for tumor behavior in squamous cell laryngeal carcinoma. Analysis of the early
(CD69+, CD71+) and the late activation antigens (CD25+high, CD26
+, HLA/DR+) expression on T CD4+ and CD8+
lymphocytes by cytofluorymetry in 55 patients treated for squamous cell laryngeal carcinoma was performed. Clini-
comorphological analysis on the basis of TNM criteria and tumor front grading, which included tumor-related
features and adjacent stroma-related characteristics of the peripheral edge of infiltration was carried out. The
relationships between the activation markers expression and parameters of tumor aggressiveness were investigat-
ed. Our work revealed statistically significant differences in the expression of the studied activation markers on
T cells with regard to certain clinicomorphological fetaures. The expressions of CD69+ and CD71+ antigens on
T CD3+CD4+ and CD3+CD8+ cells as well as CD4+HLA/DR+ markers were higher for pT3 and pT4 tumors, in
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comparison with pT2 carcinomas. Moreover, tumors with the smallest number of TFG points were characterized
by significantly lower values of the average expression of CD3+CD69+ and CD3+CD71+ as well as CD4+HLA/DR+
markers on T lymphocytes. In addition, more aggressive and deeply infiltrating laryngeal carcinomas were most
often characterized by significantly higher values of the average expression of CD69+ and CD71+ antigens on CD8+
as well as HLA/DR+ markers on CD4+. Our study confirmed the implication of the early and the late activation
antigens expression on CD4+ and CD8+ T lymphocytes in clinicomorphological parameters of the tumor, especial-
ly TFG total score and depth of invasion, and their importance as indicators of the invasive phenotype of laryngeal
carcinoma. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 593–603)
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Introduction
One of the most important challenges in contempo-
rary oncology is to find the objective biomarkers of
tumor aggressiveness, which could help to identify
more invasive phenotypes of the carcinoma. Defin-
ing the biological indicators, explicit in the assessment
and interpretation, could allow the selection of tu-
mors characterized by higher progression and there-
by to apply an appropriate and optimal treatment as
well as to predict the course of neoplastic disease in
specific cases of head and neck region cancers.
In the literature concerning this subject, many re-
searchers have pointed to the important role of immune
system disturbances in cancer patients [1–7]. In recent
years, various research centers have performed multi-ex-
perimental and clinical studies on the regulatory mecha-
nisms that determine the activity of immune system cells
in response to tumor cells of different origins. Under-
standing these immunological phenomena could have
a significant impact on the suppression of cancer progres-
sion in the future. Studies on the effects of immunocom-
petent cells involved in antitumor response to neoplastic
infiltration and the role of activation of T CD4+ and CD8+
lymphocytes in determining tumor invasiveness, as well
as the clinical course of neoplastic disease, are currently
prominent in clinical immunopathology [3, 8–11].
The purpose of this study was to investigate the
relationships between the early (CD69+, CD71+) and
the late (CD25+high, CD26
+, HLA/DR+) activation an-
tigens expression on T CD3+CD4+ and CD3+CD8+
cells subpopulations and clinicopathological charac-
teristics (pTNM classification, tumor-related and ad-
jacent stroma-related morphological features, TFG
total score) of the neoplastic infiltration in order to
determine their role as biomarkers for tumor behav-
ior in squamous cell laryngeal carcinoma.
Material and methods
Tissue samples, histological classification and morpholog-
ical features. For this study, archival paraffin-embedded tis-
sue samples from 55 patients (53 men, two women, aged
48–83 years, mean age 58.3 ± 9) surgically treated for la-
ryngeal squamous cell carcinoma were utilized. Each pa-
tient had undergone complete (60%; 33/55) or partial (40%;
22/55) surgical resection of the larynx. 40% (22/55) of the
patients underwent dissection of the cervical lymph nodes;
selective neck dissection (SND) in 36.4% (20/55) of cases;
and radical neck dissection (RND) in 3.6% (2/55) of cases.
The lesions were assessed according to the criteria of the
International Union Against Cancer (UICC-TNM 2009) for
head and neck carcinomas [12]. Morphological estimation
was performed on H&E-stained sections in accordance with
tumor front grading (TFG) classification [13, 14]. Tumor-
-related features (infiltration cytoplasmic differentiation,
nuclear polymorphism, number of mitoses) and adjacent
stroma-related characteristics of the peripheral edge of tu-
mor infiltration (mode of infiltration, depth of invasion and
plasmalymphocytic infiltration) in the most invasive, periph-
eral zones of the neoplasm were analyzed. These factors
were assessed in at least five different regions of the pe-
ripheral part of the tumor (magnification × 200, number of
mitoses magnification × 400). Each factor was graded ac-
cording to a scale ranging from 1 to 4. The total morpho-
logical TFG score was computed as the sum of six parame-
ters, with a maximum score of 24 points. According to the
results, tumors were divided into five groups: 6–9, 10–13,
14–17, 18–21 and > 22 TFG points. The histological grade
of differentiation, G, was measured according to the gener-
ally-accepted three-grade morphological system: G1 (low
grade), G2 (intermediate/moderate grade), and G3 (high
grade).The observation period of patients after surgical
treatment was at least 24 months (from 24 to 54 months).
There were no deaths among the patients included in the
research. Local recurrence of cancer was found in 5.4%
(3/55) of patients 6–18 months after a partial laryngectomy,
in whom the treatment of choice was total laryngectomy.
FACS analysis of early and late activation antigens on
T CD4+ and CD8+ lymphocytes. The investigations were per-
formed with the approval of the Ethical Committee of the
Medical University of Lodz, Poland and the National Sci-
ence Council, Poland (No RNN/15/03/KN). Blood was col-
lected directly before premedication into pyrogen free He-
parin Li-tubes (final concentration 10 U/mL) and resuspend-
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ed at a concentration of 1 × 106 cells/mL in RPMI 1640
medium (Biomed, Poland) supplemented with antibiotics
streptomycin/penicillin/gentamycin 1% v/v (Sigma, Aldrich,
Germany). Next, blood was incubated in 24-well flat-bot-
tomed plates (Nunc Corp., Roskilde, Denmark) in a final
volume of 0.2 mL (per well) and collected after 24 h at 37°C,
5% CO2 (Cellstar Incubator). The experiences with the use
of mitogenic stimulation with 5 μg of PHA (phytomaggluti-
nin) were also perfomed. For immunostaining, the follow-
ing conjugated antibodies were used: anti-CD4 FITC la-
beled (clone RPA-T4), anti-CD4 PE (SK3), anti-CD8 PE
(RPA-T8), anti-CD69 APC (L78), anti-CD71 APC
(M-A712), anti-CD25 PE (2A3), anti-CD26 PE (L272) and
anti-HLA-DR APC (L243), all provided by BD Pharmingen.
100 ml of blood was mixed and incubated for 30 min. at
room temperature with appropriate quantities of antibod-
ies or isotype controls. Erythrocyte contamination was elim-
inated by the addition of lysing solution (BD Bioscience)
into the samples. After brief incubation and rinsing, the sam-
ples were fixed with 1% paraformaldehyde and analyzed by
flow cytometry (FACSCalibur TM, CELLQuestTM soft-
ware; BD Bioscience). The cell analysis and gates were re-
stricted to lymphocytes in dot-plot. The results were ex-
pressed as mean fluorescence intensity (MFI) of the labeled
surface antigens or percent positive CD4+ or CD8+ cells.
Statistical analysis of data. The statistical calculations were
made using STATISTICA version 9.0 (StatSoft, Poland).
None of the parameters recorded in material studied passed
tests for being normally distributed (Kolmogorov–Smirnov
test). Kruskal–Wallis one-way ANOVA test as nonparamet-
ric analysis of variance by ranks and post-hoc tests (Mann–
–Whitney U test and Dunnett correction for multiple com-
parisons) for relationships between the activation antigens
expression and clinicopathologic parameters were used;
p-values £ 0.05 were considered to be significant.
Results
Clinicomophological characteristics
of group studied. The early activation antigens
(CD69+ and CD71+) and the late activation
markers (CD25+high, CD26
+, HLA/DR+)
activation antigens expression on T cells
To begin with, we studied the morphological features
according to pTNM criteria and tumor front grading
(TFG) classification in the archival paraffin-embed-
ded tissue samples of squamous cell laryngeal carci-
nomas. In this study, 25.4% (14/55) of all tumors were
classified as pT2 stage, 38.2% (21/55) as pT3, and
36.4% (20/55) as pT4. Nodal stage was histologically
assessed as pN0 in 70.9% (39/55) of cases, and as pN1-3
in the remaining 29.1% (16/55) of cases. Pathological
analysis of TFG characteristics and the total score
for tumors studied was 6–9 points in 9.1% (5/55) of
cases, 10–13 points in 30.9% (17/55) of carcinomas,
14–17 points in 41.8% (23/55) of cases and 18–20
points in 18.2% (10/55) of cases, respectively. There
were no tumors with TFG score > 21 points in the
studied group. Tumors characterized by poor cyto-
plasmic differentiation (5–20% keratinized) — 36.4%
(20/55) of cases, moderate nuclear polymorphism
(50–75% mature cells) — 45.5% (25/55), single num-
ber of mitoses (0–1) — 56.4% (31/55) as well as neo-
plastic invasion deeper than submucosa into cartilage
(19/55, 34.5%) and tumors with no distinct border-
lines (16/55, 29.1%) were the most numerous groups
of laryngeal carcinomas studied. The distribution of
tumor-related and adjacent stroma-related morpho-
logical features, according to TFG classification in the
group studied, is shown in Table 1.
The analysis showed that in the studied group mean
values of CD69+ and CD71+,  the early activation anti-
gens expression on T cells subpopulations, measured as
a percentage of T cells with positive expression, were
(% ± SEM): 11.1 ± 1.91 for CD69+ and 6.4 ± 1.31 for
CD71+ on CD3+CD4+ T cells and 15.1 ± 2.25 for CD69+
Table 1. Distribution of tumor-related and adjacent stroma-
related morphological features, according to TFG classifi-
cation in the group studied
TFG feature Characteristic n (%)
Cytoplasmic High (> 50% keratinized) 8 (14.5)
differentiation Moderate (20–50%) 17 (30.9)
Poor (5–20%) 20 (36.4)
None (< 5% ) 5 (9.1)
Nuclear High (> 75% mature cells) 18 (32.7)
polymorphism Moderate (50–75%) 25 (45.5)
Poor (25–50%) 11 (20.0)
None (< 25%) 1 (1.8)
Number Single (0–1) 31 (56.4)
of mitoses Moderate number (2–3) 13 (23.6)
Large number (4–5) 7 (12.7)
Very numerous (> 5) 4 (7.3)
Mode Well-defined borderline 12 (21.8)
of invasion Less marked borderline 15 (27.3)
No distinct borderline 16 (29.1)
Diffuse growth 12 (21.8)
Depth Carcinoma in situ (CIS) 6 (10.9)
of invasion Microinvasion into submucosa 12 (21.8)
Nodular into submucosa 18 (32.7)
Invasion of cartilage 19 (34.5)
Plasma- Marked (continuous rim) 7 (12.7)
lymphocytic Moderate (many large patches) 18 (32.7)
invasion Slight (few small patches) 24 (43.7)
None 6 (10.9)
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Table 2. Early activation antigens expression on CD3+CD4+ and CD3+CD8+ T cells with regard to chosen features
Feature Characteristic Without mitogenic stimulation (% ± SEM)
CD4+CD69+ CD8+CD69+ CD4+CD71+ CD8+CD71+
pT pT2 5.4 ± 1.52 6.4 ± 0.97 2.1 ± 0.43 0.8 ± 0.14
pT3 13.6 ± 3.37 21.5 ± 4.19 8.4 ± 2.45 6.4 ± 1.74
pT4 14.3 ± 4.24 15.6 ± 3.32 8.7 ± 2.64 5.4 ± 1.17
TFG score 6–9 points 5.6 ± 2.16 6.2 ± 0.41 2.6 ± 0.61 1.2 ± 0.22
10–13 points 8.1 ± 2.75 9.0 ± 1.71 4.3 ± 1.82 2.4 ± 0.90
14–17 points 16.6 ± 3.51 24.6 ± 4.07 10.6 ± 2.37 7.8 ± 1.68
18–21 points 7.1 ± 1.13 11.6 ± 6.84 2.0 ± 0.75 1.9 ± 0.73
Depth of invasion Carcinoma in situ (CIS) 4.9 ± 2.51 5.5 ± 1.05 2.2 ± 0.81 0.9 ± 0.29
Microinvasion 10.9 ± 3.13 17.5 ± 5.93 7.6 ± 2.96 5.5 ± 2.31
Nodular into submucosa 13.6 ± 4.57 14.9 ± 2.96 7.5 ± 2.72 4.4 ± 1.43
Invasion of cartilage 10.7 ± 2.59 16.8 ± 3.61 5.3 ± 1.27 4.3 ± 1.07
Feature Characteristic With mitogenic stimulation (% ± SEM)
CD4+CD69+ CD8+CD69+ CD4+CD71+ CD8+CD71+
pT pT2 28.1 ± 5.74 42.8 ± 6.56 22.1 ± 4.69 15.3 ±3.62
pT3 38.1 ± 5.79 49.8 ± 7.09 29.9 ± 5.87 28.2 ± 4.67
pT4 30.3 ± 7.62 41.1 ± 7.50 32.3 ± 9.19 23.2 ± 4.88
TFG score 6–9 points 31.3 ± 10.41 47.3 ± 12.76 30.6 ± 10.44 18.1 ± 9.54
10–13 points 32.6 ± 5.99 40.4 ± 6.01 22.6 ± 5.71 16.6 ± 3.51
14–17 points 37.2 ± 6.09 50.5 ± 7.38 36.6 ± 5.77 32.1 ± 4.14
18–21 points 17.4 ± 0.95 41.9 ± 11.16 9.4 ± 1.06 14.9 ± 5.61
Depth of invasion Carcinoma in situ (CIS) 20.1 ± 11.16 37.1 ± 14.29 23.6 ± 10.70 17.7 ± 9.61
Microinvasion 35.8 ± 5.82 44.6 ± 5.88 23.7 ± 5.63 20.4 ± 5.25
Nodular into submucosa 37.6 ± 7.76 50.7 ± 8.69 37.9 ± 8.07 26.4 ± 4.89
Invasion of cartilage 29.1 ± 5.03 43.1 ± 7.34 21.4 ± 4.05 23.1 ± 4.73
and 4.3 ± 0.89 for CD71+ on CD3+CD8+ subpopula-
tion, respectively. The evaluation of CD25+high, CD26
+,
HLA/DR+, the late activation markers expression on
T cells demonstrates the following results: 10.4 ± 1.4
for CD25+high, 0.3 ± 0.05 for CD26
+ and 25.4 ± 2.17 for
HLA/DR+ on T CD3+CD4+ lymphocytes and 9.9 ± 1.14
for CD25+high, 20.8 ± 2.35 for CD26
+ and 38.4 ± 2.05
for HLA/DR+ on T CD3+CD8+ cells, respectively.
The evaluation of activation markers expression
in experiments with mitogenic stimulation demon-
strated the presence of the following mean values of
the early antigens on CD3+CD4+ and CD3+CD8+
T cells (% ± SEM): 32.9 ± 3.6 for CD69+ and 27.9 ±
± 3.64 for CD71+ on CD3+CD4+ T cells and 45.4 ± 4.08
for CD69+ and 22.8 ± 2.72 for CD71+ on CD3+CD8+
subpopulation, respectively. The evaluation of the late
activation markers expression on T cells demonstrat-
ed the following results: 14.9 ± 1.4 for CD25+high,
4.6 ± 0.94 for CD26+ and 34.9 ± 2.31 for HLA/DR+
on T CD3+CD4+ lymphocytes and 13.0 ± 1.83 for
CD25+high, 26.5 ± 2.54 for CD26
+ and 45.2 ± 2.35 for
HLA/DR+ on T CD3+CD8+ cells, respectively.
Subsequently, we analyzed the relationships of the
early (CD69+, CD71+) and the late (CD25+high,
CD26+, HLA/DR+) activation antigens expression
with certain clinicopathological features with regard
to degree of tumor aggressiveness to evaluate their
possible role as potential biomarkers for tumor be-
havior in squamous cell laryngeal carcinoma.
The relationships between the early
(CD69+, CD71+) activation markers expression on
T CD3+CD4+ and CD3+CD8+ lymphocytes
and clinicopathological parameters
To investigate whether the early activation markers
such as CD69+ and CD71+ on T lymphocytes can
potentially determine clinicopathological features, the
cytofluorymetric analysis results were juxtaposed with
pathological assessment of the primary tumor (pT sta-
tus) and the regional lymph nodes (pN status), the his-
tological grade (G), the TFG total score and chosen
parameters of TFG classification. The mean expres-
sions of the early activation markers with regard to
degree of tumor aggressiveness, according to pT sta-
tus, TFG classification and the depth of invasion in the
trials without/with stimulation, are shown in Table 2.
The evaluation of the early antigens status dem-
onstrated the presence of significant differences in
CD4+CD69+ (p = 0.04) and CD8+CD69+ (p = 0.01)
expression with regard to pT feature. Data analysis
also showed statistically significant differences in the
average expression of CD4+CD71+ (p = 0.004) and
CD8+CD71+ (p = 0.01) depending on the pT status.
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The expression of CD69+ and CD71+ antigens on
T CD3+CD4+ and CD3+CD8+ cells was higher for pT3
and pT4 tumors, in comparison with pT2 carcinomas. No
significant differences between the mean expression of
early activation markers comparing tumors in various stag-
es of pN and histological differentiation were noted.
We discovered statistically significant differences
between mean values of CD69+ (p = 0.003) and
CD71+ (p = 0.01) antigen expression on T CD8+ cells
subpopulation taking into account the degree of tu-
mor invasiveness defined by TFG total score. Carci-
nomas with the smallest number of TFG points
(6–9 points) were characterized by significantly low-
er values of the average expression of CD8+CD69+
and CD8+CD71+ antigens. Our results also indicated
a significant difference between CD69+ (p = 0.006)
and CD71+ (p = 0.01) antigens on T CD3+CD8+ cells
with regard to depth of invasion. Tumors with nonin-
vasive growth (CIS) demonstrated significantly low-
er values of average percentage of the early activa-
tion markers on T CD8+ lymphocytes subpopulation.
In contrast, more aggressive and deeply infiltrat-
ing laryngeal carcinomas were most often character-
ized by significantly higher values of the average ex-
pression of CD8+CD69+ and CD8+CD71+ antigens.
No significant differences between the mean expres-
sion of early activation markers comparing tumors
with various types of invasion and the intensity of plas-
malymphocytic infiltration were disclosed. Dot plot
histograms of representative results of CD8+CD69+
and CD8+CD71+ antigens with regard to depth of
invasion are shown in Figure 1A–D. The mean ex-
pressions of the early activation markers and the sta-
tistical test results depending on TFG and the depth
of invasion are shown in Figure 2.
No significant relationships between  the mean
expression of the early antigens and the late activa-
tion markers in relation to clinicopathological char-
acteristics in the trials with stimulation were noted.
The relationships between the late (CD25+high,
CD26+, HLA/DR+) activation antigens expression
on T CD3+CD4+ and CD3+CD8+ lymphocytes
and clinicopathological parameters
To check whether the late activation molecules such
as CD25+high, CD26
+, HLA/DR+ on T CD3+CD4+ and
CD3+CD8+ cells could be associated with clinicomor-
Figure 1. Dot plot histograms of representative results of CD8+CD69+ and CD8+CD71+ antigens with regard to depth of
invasion (A) Higher expression of CD8+CD69+ (38.1%) for tumors with invasion of cartilage were demonstrated.
(B) Lower expression of CD8+CD69+ (3.6%) for CIS was noted. (C) Higher expression of CD8+CD671+ (25.6%) for
tumors with invasion of cartilage was disclosed. (D) Lower expression of CD8+CD71+ (0.3%) for CIS was noted
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phological parameters, we rated the cytofluorymet-
ric assessment against pT and pN status, the histo-
logical grade (G), the TFG total score and chosen
parameters of TFG classification. The mean expres-
sions of the late activation markers with regard to
degree of tumor aggressiveness, according to pT, TFG
classification and the depth of invasion in the trials
without/with stimulation, are shown in Table 3.
Data study showed statistically significant differ-
ences in the average expression of HLA/DR+ anti-
gens on T CD4+ cells depending on the pathologi-
cal assessment of the primary tumor (pT status)
(p = 0.009). Carcinomas with the highest local stage
pT4 were characterized by significantly higher val-
ues of the average level of CD4+HLA/DR+. No sig-
nificant differences between the mean expression of
the other late activation markers comparing tumors
in various stages of pN and histological differentia-
tion were noted.
The evaluation of the late antigens status also dem-
onstrates the presence of significant differences in
CD4+HLA/DR+ (p = 0.04) expression with regard
to various degree of tumor aggressiveness, according
to TFG total score. Carcinomas with the smallest
number of TFG points (6–9 points) were character-
ized by significantly lower values of the average ex-
pression of HLA/DR+ antigens on T CD4+ lympho-
cytes. In addition, we confirmed significant differences
of the late activation markers between various depths
of tumor invasion. Patients with carcinomas charac-
terized by the lowest values of the average expression
of CD4+HLA/DR+ on T cells were found to demon-
strate the least invasive grow. No significant differ-
ences between the mean expression of early activa-
tion markers comparing tumors with various types of
invasion and the intensity of plasmalymphocytic in-
filtration were noted. Dot plot histograms of repre-
sentative results of CD4+HLA/DR+ antigens with
Figure 2. Mean expressions of early activation markers and statistical test results with regard to (A) TFG
and (B) the depth of invasion in tumor group studied
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regard to TFG score and the depth of invasion are
shown in Figures 3A–D. The mean expressions of the
late activation markers and the statistical test results
depending on TFG score and the depth of invasion
are shown in Figure 4.
Our data demonstrated a statistically significant
increase in the average expression of CD4+HLA/DR+
activation markers when laryngeal cancers were more
extensive and pT status was higher, in the experiments
with mitogenic stimulation (p = 0.04). Increased ex-
pression of HLA/DR+ antigens on T CD3+CD4+ cells
was the highest in pT3 and pT4 tumors. We did not
discover statistically significant differences between
mean values of other antigens expression on T cells
subpopulations in relation to clinicopathological pa-
rameters in the trials with stimulation.
Discussion
This study found that laryngeal squamous cell carci-
nomas in a high local stage of neoplastic lesions (pT3
and pT4 tumors), were characterized by a significantly
higher expression of the examined early activation an-
tigens, i.e. CD4+CD69+, CD8+CD69+, CD8+CD71+,
CD8+CD71+ in comparison with pT2 carcinomas.
Among the analyzed markers of late activation,
only HLA/DR+ antigens on T CD4+ lymphocytes
showed higher expression in advanced cancers of the
larynx. It was also shown that tumors with the least
invasive changes, such as cancer with the smallest
number of points referred to the criteria of TFG clas-
sification, were characterized by the lowest expres-
sion of the early antigens CD69+ and CD71+ on
T CD8+ cells and also the lowest expression of the
late activation markers HLA/DR+ on T CD4+ cells,
in experiments without mitogen stimulation. The per-
centage of T CD4+ and CD8+ cells in circulating blood
and the ratio of CD4+/CD8+ was not significantly as-
sociated with analyzed clinicopathological parame-
ters. The results obtained in our study indicate the
occurrence of immune activation of T cells in periph-
eral blood, both T CD4+ and CD8+ cells in the early
phase of immune response to the presence of tumor
antigens in cases of laryngeal cancers in high-stage
changes. However, the observed absence of relation-
ships of the late activation markers expression on
T cells, in particular on CD8+ subpopulations with
clinicomorphological features in invasive carcinomas
of the larynx, indicates a progressive disturbance and
decrease in the effectiveness of antitumor immune
Figure 3. Dot plot histograms of representative results of CD4+HLA/DR+ antigens depending on pT status and depth of
invasion (A) Higher expression of CD4+ HLA/DR+ (51.5%) for pT4 tumors was demonstrated. (B) Lower expression of
CD4+ HLA/DR+ (8.9%) for pT2 was noted. (C) Higher expression of CD4+HLA/DR+ (35.9%) for tumors with invasion
of cartilage was disclosed. (D) Lower expression of CD4+HLA/DR+ (7.5%) for CIS was noted
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mechanisms, which progressed with increasing time
of interaction of tumor cells to immune cells.
The phenomenon of suppressive effects of tumor
on the function of cells involved in cellular immune
response can lead to anergy and immunological tol-
erance to foreign antigens in cancer patients. Also
important is the role of regulatory lymphocytes, sub-
population of CD4+ cells which, by the immunosup-
pressive activity directed against the effector cells, also
contribute to the inhibition of antitumor immune
mechanisms and increasing cancer progression [2, 6,
8, 15–23]. The causes of the dysfunction of T lym-
phocytes, both CD4+ and CD8+ cells and absence of
stimulation of cells participative in the cellular im-
mune response to tumor antigens, also include chang-
es in the level of secreted cytokines, marked in the
peripheral blood in patients with laryngeal cancer.
A lack of activation of immune mechanisms dependent
on IL-6 and IFN-g results in the reduced effective-
ness of cellular immune response to carcinoma anti-
gens. The reduction in IL-6 in the peripheral blood
can result in a decrease of the activity of T cells that
recognize antigen, impaired differentiation of anti-
gen-stimulated T cells into the cytotoxic lymphocytes,
as well as reduction in Tc and NK cells activation and
thus direct inhibition of tumor cell proliferation and
cytolytic activities [2, 3, 18, 24–27].
No effect of IFN-g promotes expression of MHC
molecules on the APC cells and enhances antigen
presentation, increases the cytotoxicity of Tc lympho-
cytes, induces expression of cytokines such as IL-1a,
IL-6, TNF, and thus stimulates the activity of CD4+
and CD8+. This confirms the immunosuppressive ef-
fects of tumor cells on T lymphocytes and indicates
a defect of the immune response caused by the mal-
functioning of immune cells [2, 3, 18, 24–27]. Sup-
pression of immune response in advanced laryngeal
cancer increases high level of secreted IL-10, which
also inhibits the expression of MHC class II molecules
on macrophages and reduces the presentation of tu-
mor antigens as well as inhibits the formation of Th1
cells and cytokine production by Th1 (IFN-g). The pre-
sented observations are therefore evidence of the in-
effectiveness of immune mechanisms, dependent on
active T lymphocytes and also indicate the efficacy of
escape mechanisms used by tumor cells in defense
against anti-tumor immune response [2, 3, 18, 24–27].
In the literature, it is difficult to find publications
in which the relationship of antigen expression on
activated T lymphocytes in laryngeal squamous cell
Table 3. Late activation antigens expression on CD3+CD4+ and CD3+CD8+ T cells with regard to chosen features
Feature Characteristic Without mitogenic stimulation (% ± SEM)
CD4+CD25+high CD8
+CD25+ CD4+CD26+ CD8+CD26+ CD4+HLA/ CD8+HLA/
/DR+ /DR+
pT pT2 9.7 ± 1.84 10.8 ± 2.01 0.2 ± 0.02 22.7 ± 2.27 16.8 ± 2.68 32.1 ± 2.74
pT3 9.1 ± 1.98 8.5 ± 1.88 0.3 ± 0.10 20.2 ± 4.03 27.7 ± 3.28 42.9 ± 3.08
pT4 13.5 ± 3.93 10.7 ± 2.31 0.4 ± 0.08 20.6 ± 4.32 32.9 ± 3.88 39.3 ± 4.48
TFG 6–9 points 11.7 ± 4.56 6.7 ± 4.30 0.2 ± 0.05 25.4 ± 3.45 18.2 ± 1.91 32.5 ± 6.28
score 10–13 points 11.2 ± 1.98 12.0 ± 1.17 0.2 ± 0.03 23.2 ± 4.96 20.7 ± 3.38 36.2 ± 12.25
14–17 points 7.4 ± 0.94 10.3 ± 2.30 0.4 ± 0.09 17.7 ± 3.09 32.8 ± 2.98 43.1 ± 10.71
18–21 points 17.8 ± 11.36 4.6 ± 1.05 0.5 ± 0.01 31.5 ± 5.01 22.2 ± 9.12 35.4 ± 11.76
Depth Carcinoma in situ (CIS) 9.5 ± 2.60 9.0 ± 3.38 0.2 ± 0.01 28.9 ± 0.01 16.0 ± 3.09 32.4 ± 3.21
of Microinvasion 11.2 ± 2.43 9.6 ± 2.38 0.3 ± 0.09 24.3 ± 5.88 22.1 ± 4.08 37.7 ± 4.22
invasion Nodular into submucosa 8.5 ± 2.02 9.0 ± 2.70 0.3 ± 0.14 14.6 ± 2.52 28.1 ± 4.33 42.1 ± 3.82
Invasion of cartilage 12.3 ± 4.06 11.3 ± 1.87 0.4 ± 0.07 23.2 ± 3.44 30.2 ± 3.11 37.1 ± 3.71
Feature Characteristic With mitogenic stimulation (% ± SEM)
CD4+CD25+high CD8
+CD25+ CD4+CD26+ CD8+CD26+ CD4+HLA/ CD8+HLA/
/DR+ /DR+
pT pT2 16.2 ± 1.80 12.2 ± 1.90 5.0 ± 1.90 31.9 ± 2.95 27.8 ± 3.51 40.5 ± 4.08
pT3 12.7 ± 2.03 10.9 ± 3.43 5.1 ± 1.73 23.9 ± 4.01 36.2 ± 3.59 47.7 ± 3.78
pT4 17.0 ± 3.35 17.4 ± 4.38 3.6 ± 0.63 27.1 ± 4.87 42.5 ± 4.04 47.0 ± 4.29
TFG 6–9 points 17.9 ± 3.50 7.5 ± 4.25 6.8 ± 3.85 36.1 ± 2.80 27.6 ± 3.20 42.4 ± 13.41
score 10–13 points 15.9 ± 1.99 13.3 ± 0.88 4.6 ± 1.60 26.5 ± 5.15 34.4 ± 4.64 43.3 ± 13.78
14–17 points 11.7 ± 1.38 14.2 ± 4.19 4.4 ± 1.39 23.2 ± 3.12 38.6 ± 2.69 49.8 ± 14.06
18–21 points 20.2 ± 9.37 14.4 ± 12.40 2.6 ± 0.01 42.8 ± 6.01 30.7 ± 9.93 36.7 ± 6.30
Depth Carcinoma in situ (CIS) 2.6 ± 0.84 9.5 ± 3.17 10.7 ± 0.01 38.9 ± 0.01 22.5 ± 4.76 40.7 ± 7.48
of Microinvasion 3.2 ± 0.65 11.3 ± 2.38 2.1 ± 0.45 28.8 ± 5.32 33.1 ± 3.67 45.2 ± 4.35
invasion Nodular into submucosa 2.4 ± 0.34 13.6 ± 6.66 3.8 ± 1.48 23.0 ± 3.11 37.7 ± 5.15 48.2 ± 5.01
Invasion of cartilage 2.8 ± 1.01 16.4 ± 3.53 7.1 ± 2.01 26.2 ± 5.54 39.5 ± 2.50 43.1 ± 2.93
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carcinoma in the context of assessing the impact of
the activity of immunocompetent cells on the clinico-
morphological parameters of the tumor has been an-
alyzed. Moreover, researches on carcinomas of the
head and neck region have mostly related to the as-
sessment of expression of the markers on tumor infil-
trating cells (TIL), rather than circulating blood cells,
which does not allow direct comparison of results
[6, 15, 28–30]. For discussion, only publications con-
cerning cancers of the head and neck region, in which
the authors had adopted similar techniques to the used
panel of activation markers on T cells, and similar
research methods, were chosen. In addition, individ-
ual research papers in which the relationships between
immunological parameters and clinicomorphological
characteristics of tumor were analyzed, related only
to typical histological markers. In these publications,
the criteria for the TNM classification, histological
grade G and the degree of clinical progression of the
laryngeal carcinoma S often were concerned with
prognostic indicators such as survival and tumor recur-
rence [6, 15, 28–30]. It should be emphasized that the
results of many authors show large discrepancies in as-
sessing the activity of cells involved in immunological
processes in various types of head and neck carcinomas
and lead to different conclusions regarding the relation
of activation markers expression on immune cells and
clinicomorphological indicators [6, 15, 28–30].
Regardless of these differences in methodology
and the importance of heterogeneity in the analyzed
groups of cancers, studies on the activity of immune
cells, which participate in immunological reactions in
the course of tumor progression, indicate varying de-
grees of intensified suppression of immune cellular
mechanisms, evaluated as the activation antigens ex-
pression on T CD4+ and CD8+ cells in squamous cell
carcinomas of the head and neck [6, 15, 19, 28–31].
The presence of increased suppression of T CD8+
cells in peripheral blood in the most advanced clini-
cal stage (IV S), indicating the abnormal relationship
Figure 4. Mean expressions of late activation antigens and statistical test results depending on (A) TFG score
and (B) the depth of invasion in carcinoma group studied
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of effector cells activity in invasive tumors of the head
and neck region, was confirmed [29]. Analysis of clini-
comorphological markers in another group of patients
with HNSCC has indicated a decreased number of
T CD4+ and CD8+ cells in circulating blood, without
demonstrating the relationships of immune cells ac-
tivity with the parameters of TNM classification [30].
In other studies, the assessment of activity of T cells
subpopulations among tumor infiltrating lymphocytes
(TIL), demonstrated the absence of relationships
between the expression of CD4+ phenotype with the
local extent of tumor pT, nodal stage pN and the pri-
mary location of tumor invasion [32]. The dependence
of the high percentage of lymphocytes with CD8+
phenotype in peripheral blood and also the presence
of a reduced ratio of CD4+/CD8+, which are associ-
ated with increased invasiveness of tumor determined
on the basis of pT in patients with tumors of the head
and neck, has also been demonstrated [6].
Other authors, however, did not confirm the cor-
relation of CD4+/CD8+ ratio with progression of neo-
plastic lesions, treatment outcomes, incidence of tu-
mor recurrences and survival in patients with carci-
nomas of the larynx [31]. In other studies on the ex-
pression of both early antigens CD69+ and CD71+ and
the late activation markers CD25+ and HLA-DR+ on
T lymphocytes in peripheral blood in relation to the
pTNM classification, there were significant correla-
tions between the analyzed indicators. The authors
found that high expression of CD71+ molecules on
T CD3+ lymphocytes and a high rate of CD69+/CD71+
as well as CD25+/HLA-DR+ were significantly asso-
ciated with increasing invasiveness of cancerous
changes according to pTNM in tumors of the head
and neck [28]. Researchers also point to the impor-
tance of the expression of various activation markers
in the progression of the neoplastic disease and thus
the role of activation antigens as prognostic indica-
tors. There have been no deaths among the patients
included in this study. Local recurrence of cancer was
found only in three patients 6–18 months after a par-
tial laryngectomy. Analysis of activation antigens ex-
pression on T lymphocytes as prognostic indicators
has not been studied in this paper, because of the pre-
viously described clinical characteristics of the group
studied. Nevertheless, the findings of other authors
indirectly indicate the role of the degree of immune
cells activity in cancer patients as well as the impor-
tance in determining the advancement of neoplastic
changes. A significant correlation of high percentage
of TIL characterized by CD4+CD69+ phenotype with
a lower risk of local recurrence and prolonged sur-
vival of patients with head and neck carcinomas has
been demonstrated. Interestingly, the increase in the
percentage of lymphocytes with CD4+Foxp3+ pheno-
type in tumor stroma was also associated with a de-
creased incidence of tumor recurrence [32]. The path-
omechanism leading to the observed changes are ex-
plained by the influence of regulatory T cells on
T CD4+CD25+Foxp3– and CD8+ lymphocyte subpop-
ulations. Treg lymphocytes, which dampen down the
activity of T CD4+ cells and CD8+ cytotoxic lympho-
cytes, leading to inhibition of the inflammatory re-
sponse, promote tumor growth, and thereby contrib-
ute to reducing tumor invasiveness and local recur-
rences. The researchers also noted a positive correla-
tion between the percentage of T CD4+CD69+ cells
with the number of T cells characterized by
CD4+CD25+ phenotype in tumor stroma, but they
did not show such a relationship for T CD4+CD69+
cells expressing CD4+Foxp3+ antigens CD4. A de-
creased percentage of TIL CD4+ lymphocytes was
associated with an absence of neoplastic recurrenc-
es but did not impact on survival. Different results
were presented by other investigators who demon-
strated a significant correlation of reduced CD4+
antigen expression on peripheral blood lymphocytes,
with an increased incidence of local recurrences in
cases of head and neck cancers [29, 30]. Other au-
thors have confirmed a positive relationship between
the number of tumor infiltrating T lymphocytes
which showed CD25+ antigen expression with pro-
longed survival in the study group [19].
A significant association of early activation anti-
gen CD71+ expression on immune cells in the circu-
lating blood with survival in the studied group of pa-
tients with cancers of the head and neck region was
also demonstrated. The results indicate the role of
CD71+ high expression as a negative prognostic fac-
tor [28]. Researchers have also shown a significant
correlation between expression of the early and the
late activation antigens and survival of patients with
HNSCC. High level of the coefficients CD69+/CD71+
and CD25+/HLA-DR+ was associated with poor prog-
nosis in the study group. The discrepancies in the re-
sults of studies assessing the role of activation anti-
gens expression on T lymphocytes as indicators of ad-
vancement of neoplastic changes, and the prognostic
significance of activity of cells involved in immunolog-
ical processes, indicate a need for further research to
obtain clear conclusions concerning the pathomecha-
nism of tumor progression in many cancers of the head
and neck, including cancers of the larynx.
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